Key result
d-Sotalol prolongs action potential duration similarly to dl-sotalol in canine models.
Why the study?
The electrophysiological effects of d-sotalol, a new drug with minimal beta-blocking action, compared to dl-sotalol on monophasic action potential duration were not established.
Does d-sotalol prolong monophasic action potential duration similarly to dl-sotalol in open-chested dogs?
Comparison
d-sotalol vs dl-sotalol administered in intravenous bolus doses
Design
Preclinical experimental study with paced heart rates
Authors
Loading...
Supports d-sotalol evaluation in humans; leaves open clinical efficacy and safety.
Does d-sotalol prolong monophasic action potential duration similarly to dl-sotalol in open-chested dogs?
d-Sotalol possesses similar class III anti-arrhythmic action (MAP prolongation) to the parent compound dl-sotalol in a canine model, suggesting potential utility in humans.
Taggart et al. (1985) studied this question. d-sotalol vs. dl-sotalol was evaluated on Monophasic action potential (MAP) duration (measured at 90% repolarization). d-Sotalol produced similar prolongation of monophasic action potential duration compared to dl-sotalol in open-chested dogs across a wide dose range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: